Glypressin

Glypressin is a prescription injectable medication containing the active ingredient terlipressin acetate. It is provided as an intravenous solution, with strength details not publicly listed. Classified as a vasopressin analog and vasopressor, Glypressin selectively stimulates V1 receptors to produce vasoconstriction and lower portal pressure in patients with severe liver disease. Marketed in the European Union, it is administered by healthcare professionals in hospital settings under close monitoring.

Glypressin is used in clinical practice to manage complications of advanced liver disease and severe circulatory disturbances where vasoconstriction is required.

- Acute variceal hemorrhage in patients with cirrhosis, administered intravenously to achieve rapid hemostasis and control bleeding. - Hepatorenal syndrome type 1, used as a short‑term vasoconstrictor to improve renal perfusion while awaiting definitive therapy. - Severe portal hypertension, where reduction of portal venous pressure helps to prevent the development of new varices. - Prevention of early rebleeding after endoscopic band ligation, providing additional vascular tone during the critical post‑procedure period. - Refractory septic shock when catecholamines are insufficient, offering an alternative mechanism to raise systemic vascular resistance.

The safety profile of Glypressin reflects its potent vasoconstrictive action; side effects are reported across a range of frequencies and may be related to the degree of vascular tone achieved during treatment.

Common: - Headache or facial flushing, often mild and transient. - Nausea, vomiting or abdominal discomfort that may resolve after infusion. - Hypertension or a temporary rise in systolic blood pressure during administration. - Peripheral edema or mild swelling of the extremities, usually reversible. - Dizziness or light‑headedness, especially when standing quickly.

Serious: - Cardiac arrhythmias or myocardial ischemia, requiring cardiac monitoring. - Severe hypertension that can precipitate cerebrovascular events such as stroke. - Ischemic necrosis of skin, digits or gastrointestinal tract, indicating critical peripheral vasoconstriction.

When prescribing Glypressin, clinicians should evaluate patient-specific factors and monitor for potential complications associated with its vasoconstrictive properties.

- Assess cardiovascular status, including history of ischemic heart disease or uncontrolled hypertension. - Use caution in patients with peripheral vascular disease or Raynaud’s phenomenon. - Monitor renal function closely, especially in those with pre‑existing renal impairment. - Observe for signs of tissue ischemia, such as pain, discoloration or loss of pulse in extremities. - Adjust dose or discontinue if severe hypertension or arrhythmias develop. - Consider fetal risk; Glypressin is contraindicated in pregnancy unless benefits outweigh potential risks.

Glypressin may interact with other agents that influence vascular tone, cardiac rhythm or renal function; awareness of these interactions helps to minimize adverse outcomes.

Avoid: - Concomitant use with other potent vasoconstrictors (e.g., norepinephrine, phenylephrine) due to additive hypertension risk. - Combination with vasodilators (e.g., nitroglycerin) that may counteract therapeutic effect. - Co‑administration with drugs that prolong QT interval, increasing arrhythmia potential.

Use with caution: - Concurrent catecholamines in septic shock; dose adjustments may be required. - Diuretics or ACE inhibitors, as they may affect blood pressure stability. - Anticoagulants, because rapid hemodynamic changes can influence bleeding risk.